TEL AVIV, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that principal investigator, Richard Penson, M.D., M.R.C.P., will present interim data from the ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Müllerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting. The reported data will include results in patients with recurrent platinum-resistant Müllerian cancer treated with multiple doses of VB-111 and weekly paclitaxel.
As the first highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth to use VBL's Vascular Targeting System™ for cancer therapy, VB-111 has the potential to treat a range of solid tumor indications by selectively targeting the blood vessels required for tumor growth and inducing apoptosis of cells in those blood vessels. VBL recently reported positive, statistically significant data evaluating the efficacy of VB-111 for the treatment of recurrent glioblastoma (rGBM), and expects to initiate a pivotal Phase 3 study in rGBM under a Special Protocol Assessment with the U.S. Food and Drug Administration in mid-2015.
Details of the presentation are as follows:
|Title:||A phase 1/2 trial of multiple dose VB-111 and weekly paclitaxel in recurrent|
|platinum-resistant Müllerian cancer|
|Time:||Saturday, May 30, 2015, 1:15 PM – 4:45 PM CT|
|Session:||Poster Session: Gynecologic Cancer|
|Authors:||Richard T Penson MD MRCP (Massachusetts General Hospital), Allison J Ambrosio BA|
|(Massachusetts General Hospital), Daphne Suzin BA BSc (Massachusetts General|
|Hospital), Siobhan A. Collins BA (Dana Farber Cancer Institute), Michael J Birrer|
|PhD (Massachusetts General Hospital), Suzanne Berlin DO (Dana Farber Cancer|
|Institute), Yael Cohen MD (VBL Therapeutics).|
VB-111 is a novel, intravenously-administered, anti-angiogenic agent that utilizes VBL's proprietary Vascular Targeting System (VTS™) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.
VB-111 completed a Phase 1/2 "all-comers" clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has Fast Track Designation for recurrent glioblastoma in the US and organ drug status for glioblastoma in both the US and EU. VBL is conducting early phase II studies in thyroid and ovarian cancer.
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 clinical trial of VB-111 in rGBM in mid-2015, under a special protocol assessment agreement granted by the FDA.
Forward Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200, email@example.com
Source: VBL Therapeutics